"Other patients requesting funding for Sunitinib will still be assessed and considered in line with the PCT's standard protocols and procedures, " a statement said.
Hampshire PCT said the National Institute for Health and Clinical Excellence (Nice) currently recommends that Sunitinib is not used for the treatment of advanced and metastatic renal cell carcinoma (kidney cancer).